Patents by Inventor Gursharan S. Chhatwal

Gursharan S. Chhatwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8956612
    Abstract: The present invention relates to a streptococcal octapeptide AXYLXXLN, and preferably to the octapeptide AXYLZZLN, designated as peptide associated with rheumatic fever (PARF) that, through its interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: February 17, 2015
    Assignee: Helmholtz-Zentrum für Infektionsforschung GmbH
    Inventors: Gursharan S. Chhatwal, Patric D. Nitsche-Schmitz, Katrin Dinkla, Vanessa Barroso
  • Patent number: 8530224
    Abstract: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these nucleic acids and polypeptides for use in the diagnosis and/or prognosis of infections with Streptococcus strains of the anginosus group. The present invention furthermore relates to methods utilizing these nucleic acids and polypeptides as well as to arrays and antibodies.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: September 10, 2013
    Assignee: Helmholtz-Zentrum für Infektionsforschung GmbH
    Inventors: Gursharan S. Chhatwal, Patric Nitsche-Schmitz, Silvana Reissmann
  • Publication number: 20120087930
    Abstract: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these nucleic acids and polypeptides for use in the diagnosis and/or prognosis of infections with Streptococcus strains of the anginosus group. The present invention furthermore relates to methods utilizing these nucleic acids and polypeptides as well as to arrays and antibodies.
    Type: Application
    Filed: June 18, 2009
    Publication date: April 12, 2012
    Inventors: Gursharan S. Chhatwal, Patric Nitsche-Schmitz, Silvana Reissmann
  • Publication number: 20100150929
    Abstract: The present invention relates to a streptococcal octapeptide AXYLXXLN, and preferably to the octapeptide AXYLZZLN, designated as peptide associated with rheumatic fever (PARF) that, through its interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.
    Type: Application
    Filed: June 1, 2007
    Publication date: June 17, 2010
    Inventors: Gursharan S. Chhatwal, Patric D. Nitsche-Schmitz, Katrin Dinkla, Vanessa Barroso
  • Publication number: 20020106376
    Abstract: A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein (SfbI) of Streptococcus pyogenes as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route either with soluble OVA or OVA covalently coupled to SfbI. Immunization with OVA-SfbI resulted in the elicitation of about 100-fold higher titres of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-SfbI also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-SfbI immunized mice also gave a much stronger proliferative response to in vitro restimulation with soluble OVA.
    Type: Application
    Filed: January 30, 2002
    Publication date: August 8, 2002
    Applicant: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Eva Medina, Gursharan S. Chhatwal, Carlos A. Guzman